Sanofi:Dupixent Phase 3 COPD Results Presented At ATS & Published In New England Journal Of Medicine
22/5 04:10
(RTTNews) - Sanofi and Regeneron Pharmaceuticals Inc. (REGN) presented positive Phase 3 results evaluating the investigational use of Dupixent (dupilumab) compared to placebo in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chroni...